Get the Stockscreener App
19.63
0.46%
-0.09
Pre-market:
19.73
0.10
+0.51%
Aktis Oncology Inc stock is traded at $19.63, with a volume of 384.70K.
It is down -0.46% in the last 24 hours and down -24.44% over the past month.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
See More
Previous Close:
$19.72
Open:
$19.74
24h Volume:
384.70K
Relative Volume:
0.89
Market Cap:
$1.09B
Revenue:
$29.71M
Net Income/Loss:
$-69.15M
P/E Ratio:
-17.45
EPS:
-1.1251
Net Cash Flow:
$-52.28M
1W Performance:
-14.13%
1M Performance:
-24.44%
6M Performance:
+5.37%
1Y Performance:
+52,669%
1-Day Range:
$19.43
$20.45
1-Week Range:
$19.43
$23.09
52-Week Range:
$14.72
$34.19
Aktis Oncology Inc Stock (AKTS) Company Profile
Name
Aktis Oncology Inc
Sector
Industry
Phone
978-237-4380
Address
17 DRYDOCK AVENUE, BOSTON, NC
Compare AKTS vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKTS
Aktis Oncology Inc
|
19.63 | 1.09B | 29.71M | -69.15M | -52.28M | -1.1251 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aktis Oncology Inc Stock (AKTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | H.C. Wainwright | Buy |
| Feb-03-26 | Initiated | BofA Securities | Buy |
| Feb-03-26 | Initiated | JP Morgan | Overweight |
| Feb-03-26 | Initiated | Leerink Partners | Outperform |
| Feb-03-26 | Initiated | TD Cowen | Buy |
| Jan-04-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-06-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-24-23 | Initiated | B. Riley Securities | Buy |
| Feb-02-21 | Reiterated | Craig Hallum | Buy |
| Jan-15-21 | Reiterated | Craig Hallum | Buy |
| Sep-18-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-10-19 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-13-19 | Reiterated | Craig Hallum | Buy |
| Feb-05-19 | Reiterated | Craig Hallum | Buy |
| Feb-05-19 | Downgrade | Northland Capital | Outperform → Market Perform |
| Dec-18-18 | Initiated | Craig Hallum | Buy |
| Nov-30-18 | Initiated | Lake Street | Buy |
| Jun-22-18 | Initiated | Loop Capital | Buy |
| Feb-09-18 | Initiated | Drexel Hamilton | Buy |
View All
Aktis Oncology Inc Stock (AKTS) Latest News
Aktis Oncology (AKTS) medical chief exercises options and sells shares under a trading plan. - Stock Titan
After selling 50,000 shares in July, an Aktis Oncology (AKTS) officer plans another sale. - Stock Titan
Aktis Oncology (NASDAQ:AKTS) Shares Down 8.6%Here's What Happened - MarketBeat
Aktis Oncology, Inc.(NasdaqGS: AKTS) added to S&P Biotechnology Select Industry Index - marketscreener.com
Tidal Investments LLC Acquires New Position in Aktis Oncology $AKTS - MarketBeat
Aktis Oncology at Morgan Stanley conference: platform bets and capital strength - Investing.com Canada
AKTS: Multi-tumor radiopharmaceuticals advance in phase I, backed by platform innovation and strong funding - TradingView
symbol__ Stock Quote Price and Forecast - CNN
AKTS Initiated Coverage by Oppenheimer -- Rating Set to Outperform - GuruFocus
Two New York investor events will include Aktis Oncology's CEO - stocktitan.net
Oppenheimer initiates Aktis Oncology stock rating at Outperform By Investing.com - Investing.com India
Oppenheimer initiates Aktis Oncology stock rating at Outperform - Investing.com
Aktis Oncology to Present at Upcoming September Investor Conferences - GlobeNewswire
Aktis Oncology (NASDAQ:AKTS) Trading Down 7.3%Should You Sell? - MarketBeat
Wellington Management Group LLP Takes $63.37 Million Position in Aktis Oncology $AKTS - MarketBeat
Aktis Oncology $AKTS Shares Purchased by BlackRock Inc. - MarketBeat
AKTS Q2 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Net LossQuarterly Profit Report - vinanet.vn
Jupiter Topco LLC Invests $42.36 Million in Aktis Oncology $AKTS - MarketBeat
Great Lakes Advisors LLC Takes $1.41 Million Position in Aktis Oncology $AKTS - MarketBeat
Blue Owl Capital Holdings LP Sells 91,129 Shares of Aktis Oncology $AKTS - MarketBeat
Aktis (AKTS) Earnings Snapshot: EPS Comes in Below Forecast in the Latest Session; Closing Reaction: The Share Price Sheds 4.08%Margin Guidance - vinanet.vn
AKTIS ONCOLOGY INC : WEDBUSH INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $35 - Bitget
Wedbush initiates Aktis Oncology stock with outperform rating By Investing.com - Investing.com South Africa
Aktis Oncology (NASDAQ:AKTS) Earns Outperform Rating from Analysts at Wedbush - MarketBeat
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play - Yahoo Finance
Wedbush Initiates Aktis Oncology at Outperform With $35 Price Target - marketscreener.com
BMO initiates Aktis Oncology stock with outperform rating By Investing.com - Investing.com Canada
AKTS Initiated Coverage by BMO Capital -- Rating Set to Outperfo - GuruFocus
Aktis Oncology (AKTS) Slips to $24.72 as Shares Trade Within Established RangeSynthetic Long - vinanet.vn
AKTS Q1 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing Oncology Pipeline InvestmentLow Growth Earnings - vinanet.vn
Aktis Oncology, Inc.: Target Price Consensus and Analysts Recommendations | AKTS | US01021M1045 - marketscreener.com
BofA Securities Maintains Aktis Oncology(AKTS.US) With Buy Rating, Maintains Target Price $34 - Moomoo
AKTS SWOT Analysis: Financial Resilience Amidst Clinical Development Challenges Revealed in 10-Q Filing - GuruFocus
Aktis Oncology (NASDAQ:AKTS) Posts Earnings Results, Meets Expectations - marketbeat.com
Aktis Oncology Q2 EPS misses estimate, sales beat consensus - scanx.trade
Aktis: Q2 Earnings Snapshot - KING5.com
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 - The Manila Times
Aktis Oncology (AKTS) builds cash to $517M as losses rise with clinical spend - Stock Titan
Aktis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Aktis Oncology (AKTS) posts Q2 2026 results with $517M cash runway into 2029 - Stock Titan
Aktis Oncology (AKTS) Gains 2.94% as Shares Approach Key Resistance at $25.34Dividend ETF - dars.gov.et
Aktis Oncology (NASDAQ:AKTS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Aktis Oncology (AKTS) Slips 1.5% as Shares Hover Above Key Support at $20.64Stop Run - vinanet.vn
AKTS Q1 2026 Earnings: Wider-than-Expected Loss of $0.38 Per Share Highlights Pre-Revenue ChallengesAnalyst Drop Coverage - vinanet.vn
AKTS Q1 2026 Earnings: Wider-than-Expected Loss of $0.38 Per Share, Yet Shares Climb 2.72%Next Quarter Guidance - careplusvn.com
AKTS Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineDividend Growth Analysis - careplusvn.com
Insider Selling: Aktis Oncology (NASDAQ:AKTS) Director Sells 4,856 Shares of Stock - MarketBeat
AKTS|Akoustis Technologies Ord Shs|Price:24.170|Chg%:+0.280 - TradingKey
Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value? - simplywall.st
AKTIS ONCOLOGY INC : LEERINK PARTNERS ASSUMES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $33 - Bitget
Aktis Oncology Inc : Leerink Partners Assumes - Moomoo
Aktis Oncology Inc Stock (AKTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aktis Oncology Inc Stock (AKTS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Czibere Akos | Chief Medical Officer |
Sep 23 '26 |
Sale |
20.69 |
12,500 |
258,621 |
0 |
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):